Small Pharma has received approval to carry out a first-in-human Phase 1 trial with its injectable deuterated DMT candidate – SPL028 – from the UK Medicines...
UK-based global nootropics company Puresport has had its Reishi, Cordyceps and Lion’s Mane supplements certified by Informed Sport, the gold-standard independent certification body.
Breaking Convention’s 11th conference, Worlds Collide, will feature themed panel discussions, art exhibitions and stalls.
Clerkenwell Health is expanding its pan-European advisory board with the addition of Dr David Erritzoe, Dr Dea Siggaard Stenbæk, Dr Kim Kuypers and Dr James Stone...
In recent weeks, much has been made of psychedelic drugs’ potential to redefine mental health treatment.
UK-startup Clerkenwell Health is opening Europe’s first ever facility to host commercial psychedelic clinical trials in London.
Leading UK psychedelics company Compass Pathways is entering into a pioneering collaboration with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate...
On International Women’s Day, Psychedelic Health takes a look at just some of the women who are spearheading the psychedelic renaissance in the UK.
The Multidisciplinary Association for Psychedelic Studies (MAPS) has been granted the Innovation Passport for MDMA as an adjunct to therapy for post-traumatic stress disorder (PTSD).
Results from a new study have demonstrated that 10mg or 25mg doses of psilocybin have no long- or short-term detrimental effects in healthy individuals.
